A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)
收藏DataCite Commons2025-09-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011584/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.
提供机构：
Vivli
创建时间：
2025-07-07
